UCB Unifies Global Pharmacovigilance Operations with Veeva Safety Suite

June 9, 2026

Veeva Systems has announced that UCB is unifying its global safety operations with the Veeva Safety Suite to enhance operational efficiency and scalability. UCB is standardizing its safety processes on a single platform aimed at expediting case processing, improving oversight, and streamlining submissions to health authorities.

The Veeva Safety Suite will be utilized by UCB for end-to-end safety management. This includes using Veeva Safety for the intake, processing, and submission of adverse events, and Veeva SafetyDocs for managing all safety-related content and processes. Additionally, Veeva Safety Workbench will facilitate advanced data analysis for rapid and scalable reporting, while Veeva Safety Signal is set to automate signal detection to improve visibility and alignment within the organization. The Veeva Safety-RIM Connection will also enable automatic sharing of product information across regulatory and safety operations, ensuring clean and trusted data.

John Lawrie, vice president of Veeva Safety, stated, "UCB is building a foundation powered by Veeva Safety Suite to simplify and standardize their global pharmacovigilance function. With a unified and connected approach, UCB is enhancing global compliance and driving advanced automation to deliver safe and effective medicines to patients."

Veeva Systems provides cloud-based software solutions, artificial intelligence, data services, and consulting for the life sciences industry. The company emphasizes innovation, product excellence, and customer success, serving over 1,500 clients ranging from major pharmaceutical firms to emerging biotechnology companies. As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves.

The announcement includes forward-looking statements regarding Veeva's products and anticipated outcomes from their usage. These statements are based on current expectations and actual results may differ materially. Various risks that could negatively impact outcomes are detailed in their filing on Form 10-Q for the fiscal year ended April 30, 2026, and in subsequent SEC filings.

Disclaimer: This press release has been distributed on behalf of the issuing organization. PR Gun acts solely as a distribution platform and has not independently verified the accuracy, completeness, or validity of the statements contained herein.